Please wait
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2024
COMMISSION FILE NUMBER 001-38455
MorphoSys AG
Semmelweisstrasse 7
82152 Planegg
Germany
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨
On July 18, 2024, MorphoSys AG (the “Company”) published a notification on receipt of a letter of intent from Novartis BidCo Germany AG (pursuant to Section 43 (1) WpHG).
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
MORPHOSYS AG (Registrant)
Date: July 18, 2024
By: /s/ i.A. Kristina Grötsch
Name: Kristina Grötsch
Title: Manager Investor Relations
By: /s/ i.A. Isabelle Degbegni
Name: Isabelle Degbegni
Title: Director Investor Relations